House Bill No. 3717 proposes the establishment of a grant program under Chapter 491 of the Health and Safety Code to fund drug development trials for ibogaine, aimed at securing its approval as a treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The bill outlines the responsibilities of the Health and Human Services Commission, which will administer the program, including the creation of a selection committee composed of subject matter experts, philanthropic partners, and legislative designees to review applications and recommend suitable candidates for conducting the trials.

The bill also details the application process for potential grant recipients, requiring them to demonstrate their capacity to conduct the trials, provide comprehensive plans for trial design, and ensure access to treatment for uninsured individuals post-approval. Additionally, it mandates that selected applicants contribute an amount equal to the grant received towards the development costs of ibogaine treatment. The commission is authorized to utilize appropriated funds and accept donations to support the grant program, with provisions for delaying implementation if federal waivers are needed. The act is set to take effect immediately upon receiving a two-thirds vote from both houses or on September 1, 2025, if that threshold is not met.

Statutes affected:
Introduced: ()
House Committee Report: ()